WO2007141283A2 - Salts and crystalline salt forms of an 2-indolinone derivative - Google Patents

Salts and crystalline salt forms of an 2-indolinone derivative Download PDF

Info

Publication number
WO2007141283A2
WO2007141283A2 PCT/EP2007/055541 EP2007055541W WO2007141283A2 WO 2007141283 A2 WO2007141283 A2 WO 2007141283A2 EP 2007055541 W EP2007055541 W EP 2007055541W WO 2007141283 A2 WO2007141283 A2 WO 2007141283A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
methylcarbonyl
anilino
piperazin
methoxycarbonyl
Prior art date
Application number
PCT/EP2007/055541
Other languages
French (fr)
Other versions
WO2007141283A3 (en
Inventor
Peter Sieger
Werner Rall
Guenter Linz
Mihaela Pop
Jaroslaw Mazurek
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to CA002653527A priority Critical patent/CA2653527A1/en
Priority to AU2007255393A priority patent/AU2007255393A1/en
Priority to BRPI0711956-9A priority patent/BRPI0711956A2/en
Priority to EP07729916A priority patent/EP2029533A2/en
Priority to MX2008015646A priority patent/MX2008015646A/en
Priority to JP2009513684A priority patent/JP2009539798A/en
Priority to US12/303,278 priority patent/US20090318471A1/en
Publication of WO2007141283A2 publication Critical patent/WO2007141283A2/en
Publication of WO2007141283A3 publication Critical patent/WO2007141283A3/en
Priority to IL195679A priority patent/IL195679A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to new salts and crystalline salt forms of an indolinone derivative, namely of the compound 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)- methylcarbonyl)-N-methyl-amino)-anilino)-l -phenyl-methylene] -6-methoxycarbonyl-2- indolinone, which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
  • the monoethanesulfonate salt of this compound is known from WO 04/13099 in its crystalline hemihydrate form, as well as a process for its manufacture.
  • the above mentioned patent applications further disclose the use of this compound or its monoethanesulfonate salt for the preparation of pharmaceutical compositions intended especially for the treatment of diseases characterized by excessive or abnormal cell proliferation.
  • WO 04/17948 discloses the use of this compound for the preparation of pharmaceutical compositions for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
  • the aim of the present invention is to provide new salts and crystalline salt forms of the compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone as such which are characterized by advantageous physicochemical properties.
  • Another object of the invention is to provide new salts and crystalline salt forms of the compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone as such which are characterized by unexpected, new pharmacological properties.
  • the invention relates to a process for the preparation of the new salts and crystalline salt forms of the compounds of formula (I), optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, and optionally to the hydrates and/or solvates thereof.
  • the free base of the compound of formula (I) is dissolved in a suitable solvent, such as 2,2,2-trifiuoro-ethanol.
  • a suitable solvent such as 2,2,2- trifluoroethano I/water (50:50) or water (depending on the acid).
  • the free base of the compound of formula (I) is then mixed with the acid at a predetermined base /acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid.
  • the solvent is evaporated under reduced pressure. After evaporation of the solvent has occurred, a suitable crystallization solvent is added to the reaction mixture, and the reaction mixture is slowly heated up to 50 0 C.
  • butylethyl ether, ethanol/water 80:20, nitrobenzene, cyclohexanone, ethyl phenyl ether, 2 - nitropropane, tert. butylmethyl ether and isobutanol.
  • the reaction mixture is slowly cooled down to a suitable crystallization temperature, which is for example between 20 0 C or 3°C. The reaction mixture stays at this temperature until enough crystals are formed, which can then be collected, for example by filtration.
  • the process is illustrated by the following example of manufacturing process of the salts and crystalline salt forms, as can be done in parallel in 96 well assay plates (maximum volume of each well is about 200 ⁇ l).
  • Each well of the 96 well plates is loaded with the free base of the compound of formula (I) as dissolved in 2,2,2-trifluoroethanol and with the acid as dissolved in the mixture of 2,2,2-trifluoroethano I/water (50:50) or just in water as far as the L-aspartic acid is concerned, such that the molar ratio of the compound of formula (I) to the respective acid is set according to the information given in Table 1 under "ratio base/acid”.
  • the 96 well plates are then placed in a vacuum chamber (1 kPa) at room temperature for 24 h in order to evaporate the solvent.
  • a preferred embodiment according to the invention thus relates to the preparation of the new salts and crystalline salt forms of the compound in accordance with formula (I) as specified hereinbefore.
  • the invention relates to solutions containing the compound of formula (I) dissolved or suspended, preferably dissolved in a solvent.
  • the solvent is an alcohol, preferably 2,2,2-trifluoro-ethanol.
  • the invention relates to specific crystalline forms of the compound of formula (I), which are discussed and characterized in detail below.
  • the harvested crystals may be characterized by X-ray powder diffraction and thermal analysis (DSC and in some cases also TGA). If suitable single crystals grow, single crystal X-ray structure analysis may be performed. The following equipment was used to characterize the crystalline salts forms.
  • XRPD patterns were obtained using a high throughput XRPD set-up.
  • the plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector.
  • the diffractometer was calibrated using Silver Behenate for the long d-spacings and corundum for the short d-spacings.
  • the data collection was carried out at room temperature using monochromatic CuK ⁇ radiation in the region of 2 ⁇ between 1.5 and 41.5 °.
  • the diffraction pattern of each well was collected with an exposure time of 3 - 4 minutes.
  • Suitable single crystals were selected and glued to a glass fibre, which is mounted on a X-ray diffraction goniometer.
  • X-ray diffraction data were collected for the mounted crystals at a temperature of 233 K using a KappaCCD system and MoK ⁇ radiation generated by a FR590 X-ray generator (Bruker Nonius Delft, The Netherlands).
  • Unit-cell parameters and crystal structure were determined and refined using the software package maXus (Mackay et al, 1997).
  • Table 2 Thermal analysis, stoichiometry and single crystal data of the different salts of the compound 3-Z-[1 -(4-(N-((4-methyl-piperazin-1 -yl)- methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6- methoxycarbonyl-2-indolinone
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2
  • R [l>2 ⁇ (l)] Final R indices [l>2sigma(l)]
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2
  • R [l>2 ⁇ (l)] Final R indices [l>2sigma(l)]
  • Fw formula weight
  • T Temperature of data collection
  • ⁇ wavelength of X-ray source
  • D m calculated density
  • ⁇ range Theta range of data collection
  • S Goodness-o- fit on F 2 ;
  • Table XXIV - 4.11b X-ray powder reflections (up to 30 ⁇ ) and intensities (normalized) of D-Tar2 D-tartrate, form Il
  • Table XXV - 4.12b X-ray powder reflections (up to 30 and intensities (normalized) of L-Ta r2 L-tartrate, form Il
  • the present invention relates to the following salts and/or crystalline forms and/or crystalline salt forms of the compound 3- Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone:
  • a further object of the present invention is the use of the above salts and crystalline salt forms as medicament for the treatment or prevention of the following diseases.
  • the diseases which can be treated by the salts and crystal salt forms of the compound of formula (I) in accordance with the present invention are all kind of diseases in which cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis are involved, which can be of oncological nature such as all types of malignant neoplasias or cancers, or of non-oncological nature, such as diabetic retinopathy, rheumatoid arthritis, or psoriasis.
  • selected specific target indications are solid tumours, such as urogenital cancers (such as prostate cancer, renal cell cancers, bladder cancers), gynecological cancers (such as ovarian cancers, cervical cancers, endometrial cancers), lung cancer, gastrointestinal cancers (such as colorectal cancers, pancreatic cancer, gastric cancer, oesophageal cancers, hepatocellular cancers, cholangiocellular cancers), head and neck cancer, malignant mesothelioma, breast cancer, malignant melanoma or bone and soft tissue sarcomas, and haematologic neoplasias, such as multiple myeloma, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome and acute lymphoblastic leukemia.
  • urogenital cancers such as prostate cancer, renal cell cancers, bladder cancers
  • gynecological cancers such as ovarian cancers, cervical
  • the underlying mechanism by which the above-mentioned diseases may be treated is via antagonism of at least one receptor selected from VEGFR 1 to 3, PDGFR ⁇ and ⁇ , FGFRl, 2 and 3, EGFR, HER2, IGFlR, HGFR, c-Kit, or a src tyrosine kinase family member.
  • the diseases which can be treated by the salts and crystal salt forms of the compound of formula (I) in accordance with the present invention are also diseases which result from aberrant activity of the following tyrosine kinases: ABL, FGFR3, FLT3 and RET.
  • Kidney Wilm's tumor soft tissue osteosarcoma, glioblastoma multiforme
  • Ph+ leukemias such as chronic myelogeneous leukemia (CML) or acute lymphocytic leukemia (ALL)
  • epithelial cancers such as bladder and cervix cancers, multiple myeloma, hepatocellular carcinoma, skeletal abnormalities such as achondroplasia and hypochondraplasia, leukemias including acute myeloid leukemia (AML), AML with trilineage myelodysplasia (AML/TMDS), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), cancers of the nerve tissue such as neuroblastoma, multiple endocrine neoplasias type 2A and 2B (MEN2A and MEN2B), familial medullary thyroid carcinomas (FMTC), papillary thyroid carcinomas (PTC) and breast cancer.
  • CML chronic myelogen
  • the diseases which may be treated with the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are immunologic disease or pathological condition involving an immunologic component.
  • diseases are, for example, autoimmune diseases, for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from inflammatory bowel disease (e.g. colitis ulcerosa and Morbus Crohn), rheumatoid arthritis, glomerulonephritis and lung fibrosis, psoriasis, psoriasis arthritis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes, and indications which need immunosuppressant therapy, for instance prevention or therapy of tissue or organ transplant rejection.
  • the underlying mechanism by which the above-mentioned diseases may be treated is via antagonism of the Lck tyrosine kinase, a tyrosine kinase belonging to the src family.
  • the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are suitable for the treatment of specific fibrotic diseases selected from the group consisting of fibrosis and remodeling of lung tissue in chronic obstructive pulmonary disease, fibrosis and remodeling of lung tissue in chronic bronchitis, fibrosis and remodeling of lung tissue in emphysema, lung fibrosis and pulmonary diseases with a fibrotic component, fibrosis and remodeling in asthma, fibrosis in rheumatoid arthritis, virally induced hepatic cirrhosis, radiation- induced fibrosis, post angioplasty restenosis, chronic glomerulonephritis, renal fibrosis in patients receiving cyclosporine and renal fibrosis due to high blood pressure, diseases of the skin with a fibrotic component, and excessive scarring.
  • specific fibrotic diseases selected from the group consisting of fibrosis and remodeling of lung tissue in chronic obstructive pulmonary disease
  • preferred diseases which my be treated with the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are lung fibrosis and pulmonary diseases with a fibrotic component selected from idiopathic pulmonary fibrosis, giant cell interstitial pneumonia, sarcodosis, cystic fibrosis, respiratory distress syndrome, drug-induced lung fibrosis, granulomatosis, silicosis, asbestosis, systemic scleroderma, the virally induced hepatic cirrhosis selected from hepatitis C induced hepatic cirrhosis, and the diseases of the skin with a fibrotic component selected from scleroderma, sarcodosis and systemic lupus erythematosus.
  • a fibrotic component selected from idiopathic pulmonary fibrosis, giant cell interstitial pneumonia, sarcodosis, cystic fibrosis, respiratory distress syndrome, drug-induced lung
  • the present invention further relates to the use of the salts and crystal salt forms of the compound of above formula (I) for the preparation of a medicament for the treatment or prevention of the above-mentioned fibrotic diseases.
  • the treatment of the diseases may also be via simultaneous, separate or sequential co-administration of effective amounts of one or more salts and crystal salt forms of the compound of formula (I) in accordance with the present invention and at least a further chemotherapeutic or naturally occurring, semi- synthetic or synthetic therapeutic agent, in the form of a combined preparation, which if necessary may optionally be adapted for a co-treatment with radiotherapy or radio-immunotherapy.
  • the present invention also relates to a process for the treatment of the above-mentioned diseases, characterized in that one or more of the above-mentioned salts or crystal salt forms of the compound of formula (I) are administered in therapeutically effective amounts to a patient in need thereof.
  • the present invention further relates to processes for the treatment of the aforementioned diseases, characterized in that one or more of the above-mentioned salts or crystal salt forms of the compound of formula (I) are administered once or several times a day or once or several times a week in therapeutically effective amounts.
  • the present invention also relates to pharmaceutical compositions comprising the above-mentioned salts or crystalline salt forms.
  • the physicochemical properties of a drug substance may influence decisively stability, usefulness and efficacy of the formulation.
  • the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention show advantageous properties not yet disclosed in the art.
  • Suitable preparations for the pharmaceutical compositions in accordance with the present invention include for example tablets, capsules, suppositories, solutions, - particularly solutions for injection (s.c, Lv., i.m.) and infusion - elixirs, emulsions or dispersible powders.
  • the proportion of the pharmaceutically active compound(s) should be in the range from 0.01 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage necessary to achieve a therapeutic effect. If necessary the doses specified may be given several times a day.
  • Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert d
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core may also consist of a number of layers.
  • the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • a sweetener such as saccharine, cyclamate, glycerol or sugar
  • a flavour enhancer e.g. a flavouring such as vanillin or orange extract.
  • suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.
  • isotonic agents e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aid
  • Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g.
  • pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly disper
  • lignin e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone
  • lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate.
  • the preparations are administered by the usual methods, preferably by oral route, by injection or transdermally.
  • the tablets may of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like.
  • lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process.
  • the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
  • solutions of the active substances with suitable liquid carriers may be used.
  • the dosage for intravenous use is from 1 - 1000 mg per hour, preferably between 5 and 500 mg per hour.
  • Composition 1 tablet core contains active substance calcium phosphate polyvinylpyrrolidone carboxymethylcellulose sodium silicon dioxide magnesium stearate
  • Preparation (direct compression): The active substance is mixed with all components, sieved and compressed in a tablet-making machine to form tablets of the desired shape.
  • the tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose.
  • Weight of coated tablet 240 mg.
  • Composition 1 tablet contains active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg hydroxypropylmethylcellulose 4.0 mg magnesium stearate 2.0 mg 220.0 mg
  • the active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the hydroxypropylmethylcellulose. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50 0 C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
  • Tablet containing 150 mg of active substance Composition 1 tablet contains active substance 150.0 mg lactose 85.0 mg microcrystalline cellulose 40.0 mg polyvinylpyrro lidone 10.0 mg silicon dioxide 10.0 mg magnesium stearate 5.0 mg
  • the active substance mixed with lactose, polyvinylpyrrolidone,and parts of the microcrystalline cellulose, magnesium stearate is compacted e.g. on a roller compactor.
  • the ribbons are broken up in fine granules through a screen with a mesh size of 0.8 mm. After subsequent sieving through a screen with a mesh size of 0.5 mm and blending with the remaining components, tablets are pressed from the mixture.
  • Composition 1 capsule contains active substance 150.0 mg lactose 85.0 mg microcrystalline cellulose 40.0 mg polyvinylpyrrolidone 10.0 mg silicon dioxide 10.0 mg magnesium stearate 5.0 mg
  • Capsule filling approx. 300 mg
  • Capsule shell size 1 hard gelatine capsule
  • 1 suppository contains: active substance 150.0 mg polyethyleneglycol 1500 800.0 mg polyethyleneglycol 6000 850.0 mg polyoxyl 40 hydrogenated castor oil 200.0 mg
  • the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
  • 100 ml of suspension contains: active substance 1.00 g carboxymethylcellulose sodium 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.0O g
  • the distilled water is heated to 70 0 C.
  • the methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring.
  • the solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring.
  • the suspension is evacuated with stirring to eliminate air.
  • 5 ml of suspension contains 50 mg of active substance.
  • composition active substance 50.0 mg
  • the active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with sodium chloride, filtered sterile and transferred into a 10 ml ampoule.
  • 1 capsule contains: active substance 5.0 mg lactose for inhalation 15.0 mg
  • Preparation The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg).
  • 1 spray contains: active substance 2.500 mg benzalkonium chloride 0.001 mg
  • the active substance and benzalkonium chloride are dissolved in ethanol/water (50/50).
  • the pH of the solution is adjusted with IN hydrochloric acid.
  • the resulting solution is filtered and transferred into suitable containers for use in hand- held nebulisers (cartridges).

Abstract

The present invention relates to new salts and crystalline salt forms of an indolinone derivative which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.

Description

NEW SALTS AND CRYSTALLINE SALT FORMS OF AN INDOLINONE
DERIVATIVE
The present invention relates to new salts and crystalline salt forms of an indolinone derivative, namely of the compound 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)- methylcarbonyl)-N-methyl-amino)-anilino)-l -phenyl-methylene] -6-methoxycarbonyl-2- indolinone, which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
Background to the invention
The compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone is known from WO 01/27081 and has the following chemical structure, depicted below as Formula (I)
Figure imgf000002_0001
Furthermore, the monoethanesulfonate salt of this compound is known from WO 04/13099 in its crystalline hemihydrate form, as well as a process for its manufacture. The above mentioned patent applications further disclose the use of this compound or its monoethanesulfonate salt for the preparation of pharmaceutical compositions intended especially for the treatment of diseases characterized by excessive or abnormal cell proliferation.
Furthermore, WO 04/17948 discloses the use of this compound for the preparation of pharmaceutical compositions for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
Summary of the invention
The aim of the present invention is to provide new salts and crystalline salt forms of the compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone as such which are characterized by advantageous physicochemical properties.
Another object of the invention is to provide new salts and crystalline salt forms of the compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone as such which are characterized by unexpected, new pharmacological properties.
Detailed description of the invention
The invention relates to a process for the preparation of the new salts and crystalline salt forms of the compounds of formula (I), optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, and optionally to the hydrates and/or solvates thereof.
Process for the preparation of the salts In the process according to the invention the free base of the compound of formula (I) is dissolved in a suitable solvent, such as 2,2,2-trifiuoro-ethanol. The acid used for the crystallization is dissolved as well in a suitable solvent, such as 2,2,2- trifluoroethano I/water (50:50) or water (depending on the acid). The free base of the compound of formula (I) is then mixed with the acid at a predetermined base /acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid. Then, the solvent is evaporated under reduced pressure. After evaporation of the solvent has occurred, a suitable crystallization solvent is added to the reaction mixture, and the reaction mixture is slowly heated up to 500C. Suitable solvents for the crystallization are tetrahydrofurane, dichloromethane, water, methanol, n-butylacetate, 1,2- dimethoxyethane, 2,2,2-trifluoroethanol (TFE)/water = 8:2, acetone/ dimethylsulfoxide (DMSO) = 8:2, chloroform, acetonitrile, ethanol, l-methyl-2-pyrrolidinone (NMP)/water = 80:20, propyl acetate, tert. butanol, 1,4-dioxane, ethyl acetate, propionitrile, di-isopropyl ether, tert. butylethyl ether, ethanol/water = 80:20, nitrobenzene, cyclohexanone, ethyl phenyl ether, 2 - nitropropane, tert. butylmethyl ether and isobutanol. After staying for about 30 minutes at 500C, the reaction mixture is slowly cooled down to a suitable crystallization temperature, which is for example between 200C or 3°C. The reaction mixture stays at this temperature until enough crystals are formed, which can then be collected, for example by filtration.
The process is illustrated by the following example of manufacturing process of the salts and crystalline salt forms, as can be done in parallel in 96 well assay plates (maximum volume of each well is about 200 μl).
Approximately 1 g of the free base of the compound of formula (I) is dissolved in 10 ml of 2,2,2-trifluoroethanol. The acids used to prepare the salts are dissolved in 2,2,2- trifluoroethano I/water (50:50) or just in water as far as the L-aspartic acid is concerned. Each well of the 96 well plates is loaded with the free base of the compound of formula (I) as dissolved in 2,2,2-trifluoroethanol and with the acid as dissolved in the mixture of 2,2,2-trifluoroethano I/water (50:50) or just in water as far as the L-aspartic acid is concerned, such that the molar ratio of the compound of formula (I) to the respective acid is set according to the information given in Table 1 under "ratio base/acid". The 96 well plates are then placed in a vacuum chamber (1 kPa) at room temperature for 24 h in order to evaporate the solvent. Afterwards, different solvents are added in each well according to the information given in Table 1 under "crystallization solvent", and the well plates are sealed and heated up to 50 0C at a heating rate of approx. 5 °C/min. The plate stays then for an additional 30 minutes at 50 0C. Afterwards, the plate is cooled at a cooling rate of 5°C/h to a final temperature of 3 or 20 0C according to the information given in Table 1 under "Tfmai[°C]". At this temperature, the plates remain for a holding time of 24 h. The plates are then opened and the solids are collected by filtration.
Table 1 : Conditions for the preparation of the different salts of the compound 3-Z-[1 -(4-(N-((4-methyl-piperazin-1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2- indolinone
Figure imgf000005_0001
Figure imgf000006_0001
Figure imgf000007_0001
Figure imgf000008_0001
Figure imgf000009_0001
* TFE = 2,2,2-trifluoroethanol
* DMSO = dimethylsulfoxide
* NMP = 1-methyl-2-pyrrolidinone
A preferred embodiment according to the invention thus relates to the preparation of the new salts and crystalline salt forms of the compound in accordance with formula (I) as specified hereinbefore.
In another embodiment, the invention relates to solutions containing the compound of formula (I) dissolved or suspended, preferably dissolved in a solvent. In a preferred embodiment, the solvent is an alcohol, preferably 2,2,2-trifluoro-ethanol.
In particular, the invention relates to specific crystalline forms of the compound of formula (I), which are discussed and characterized in detail below.
Analytical methods for the characterization of the salts The harvested crystals may be characterized by X-ray powder diffraction and thermal analysis (DSC and in some cases also TGA). If suitable single crystals grow, single crystal X-ray structure analysis may be performed. The following equipment was used to characterize the crystalline salts forms.
X-ray powder diffraction (= XRPD)
XRPD patterns were obtained using a high throughput XRPD set-up. The plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector. The diffractometer was calibrated using Silver Behenate for the long d-spacings and corundum for the short d-spacings.
The data collection was carried out at room temperature using monochromatic CuKα radiation in the region of 2Θ between 1.5 and 41.5 °. The diffraction pattern of each well was collected with an exposure time of 3 - 4 minutes.
Single crystal X-ray structure analysis
Suitable single crystals were selected and glued to a glass fibre, which is mounted on a X-ray diffraction goniometer. X-ray diffraction data were collected for the mounted crystals at a temperature of 233 K using a KappaCCD system and MoKα radiation generated by a FR590 X-ray generator (Bruker Nonius Delft, The Netherlands). Unit-cell parameters and crystal structure were determined and refined using the software package maXus (Mackay et al, 1997).
Thermal analysis (DSC and TGA)
Melting properties were obtained from differential scanning calorimetry (= DSC) thermograms recorded on a DSC822e (Mettler-Toledo GmbH, Switzerland). The DSC822e was calibrated for temperature and enthalpy with a small piece of indium (Tfus = 156.6 0C, ΔHfus = 28.45 J/g). Samples were sealed in standard 40 μl aluminium pans and heated in the DSC from 25 to 300 0C with a heating rate of 20 °C/min. Dry nitrogen gas was used to purge the DSC equipment during measurements at a flow rate of 50 ml/min.
The mass loss due to solvent or water loss from the crystals was determined by thermo gravimetric analysis (= TGA). During heating of a sample in a TGA/SDTA851e (Mettler-Toledo GmbH, Switzerland) the weight of the sample was monitored resulting in a weight vs. temperature curve. The TGA/SDTA851e was calibrated for temperature with indium and aluminium. Samples were weighed in 100 μl corundum crucibles and heated in the TGA from 25 to 300 0C with a heating rate of 20 °C/min. Dry nitrogen gas was used for purging.
The results of the characterization of the new salt forms of the compound of formula (I) are shown below in Table 2. In this table, reference is made to Tables 3.1 to 3.20, which shows the single crystal data of the salt forms, and to Figures I - 4.1 to LVIII - 4.28 and Tables I - 4.1 to LVIII - 4.28, which shows the X-ray Powder Diffraction (XRPD) diagram and the X-ray powder reflections and intensities of the crystalline salt forms in accordance with the present invention.
Table 2: Thermal analysis, stoichiometry and single crystal data of the different salts of the compound 3-Z-[1 -(4-(N-((4-methyl-piperazin-1 -yl)- methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6- methoxycarbonyl-2-indolinone
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Lh
Figure imgf000019_0001
Figure imgf000019_0002
Table 3.1 Single crystal data and structure refinement of
Bas1 = free base (= hemihydrate)
Figure imgf000020_0001
Figure imgf000021_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.2 Single crystal data and structure refinement of HBr2 = bromide, Form Il (trihydrate)
Figure imgf000021_0002
Figure imgf000022_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.3 Single crystal data and structure refinement of Pho2 = phosphate, Form Il (3,5 - hydrate)
Figure imgf000022_0002
Figure imgf000023_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.4 Single crystal data and structure refinement of Mes1 = mesylate, Form I (= hem i hydrate)
Figure imgf000023_0002
Figure imgf000024_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.5 Single crystal data and structure refinement of Ise1 = isethionate, Form I (= anhydrous form)
Figure imgf000024_0002
Figure imgf000025_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.6 Crystal data and structure refinement of Ise5 = isethionate, Form V (= di hydrate)
Figure imgf000026_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)] Table 3.7 Crystal data and structure refinement of Bes1 = besylate, Form I (= trihydrate)
Figure imgf000027_0001
R indices (all data) R1 = 0.0794, wR2 = 0.1543
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.8 Crystal data and structure refinement of Tos1 = tosylate, Form I (= monohydrate)
Figure imgf000028_0001
Figure imgf000029_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.9 Crystal data and structure refinement of Tos2 = tosylate, Form Il (= tri hydrate)
Figure imgf000029_0002
Figure imgf000030_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.10 Crystal data and structure refinement of
Cas3 = camphorsulfonate, Form III (= anhydrous form)
Figure imgf000030_0002
Figure imgf000031_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.11 Crystal data and structure refinement of Cas5 = camphorsulfonate, Form V (= hemisolvate with propionitrile)
Empirical formula C3IH34N5O4 • C10H15O4S" • 0.5 C3H5N
Figure imgf000032_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2; R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.12 Crystal data and structure refinement of
Cas12 = camphorsulfonate, Form XII (= hemisolvate with 1,2-dimethoxyethane)
Figure imgf000033_0001
Figure imgf000034_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.13 Crystal data and structure refinement of Cit2 = citrate, Form Il (= dihydrate)
Figure imgf000034_0002
Figure imgf000035_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.14 Crystal data and structure refinement of L-Lac1 = L-lactate, Form I (= 2.5 - hydrate)
Figure imgf000035_0002
Figure imgf000036_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.15 Crystal data and structure refinement of L-Mal3 = L-malate, Form III (= tetrahydrate)
Figure imgf000037_0001
Figure imgf000038_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.16 Crystal data and structure refinement of Suc3 = succinate, Form III (= hexahydrate)
Figure imgf000038_0002
Figure imgf000039_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.17 Crystal data and structure refinement of Gen11 = gentisate, Form Xl (= hemihydrate)
Figure imgf000039_0002
Figure imgf000040_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.18 Crystal data and structure refinement of Man1 = mandelate, Form I (= monohydrate)
Figure imgf000040_0002
Figure imgf000041_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.19 Crystal data and structure refinement of Sal2 = salicylate, Form Il (= anhydrous form)
Figure imgf000042_0001
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2; R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Table 3.20 Crystal data and structure refinement of Xi n1 = xinafoate, Form I (= monohydrate)
Figure imgf000043_0001
R indices (all data) R1 = 0.1066, wR2 = 0.1498
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; Dm = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F2;
R [l>2σ(l)] = Final R indices [l>2sigma(l)]
Brief description of the Figures
Figure I - 4.1a: X-ray powder diffraction diagram of HCIl = chloride, form I
(anhydrous) Figure II - 4.1b: X-ray powder diffraction diagram of HC12 = chloride, form II
(hydrated form)
Figure III - 4.2a: X-ray powder diffraction diagram of HBr7 = bromide, form VII
(anhydrous form)
Figure IV - 4.2b: X-ray powder diffraction diagram of HBr8 = bromide, form VIII Figure V - 4.3: X-ray powder diffraction diagram of Phol = phosphate, form I
Figure VI - 4.4a: X-ray powder diffraction diagram of SuIl = sulfate, form I (hydrated form)
Figure VII - 4.4b: X-ray powder diffraction diagram of Sul5 = sulfate, form V
Figure VIII - 4.4c: X-ray powder diffraction diagram of Sul6 = sulfate, form VI (hydrated form)
Figure IX - 4.4d: X-ray powder diffraction diagram of Sul7 = sulfate, form VII
Figure X - 4.5a: X-ray powder diffraction diagram of Eds 1 = edisylate, form I
Figure XI - 4.5b: X-ray powder diffraction diagram of Eds2 = edisylate, form II
Figure XII - 4.5c: X-ray powder diffraction diagram of Eds5 = edisylate, form V Figure XIII - 4.5d: X-ray powder diffraction diagram of Eds6 = edisylate, form VI
Figure XIV - 4.6a: X-ray powder diffraction diagram of Ise2 = isethionate, form II
Figure XV - 4.6b: X-ray powder diffraction diagram of Ise4 = isethionate, form IV
Figure XVI - 4.7a: X-ray powder diffraction diagram of Bes3 = besylate, form III
(anhydrous form) Figure XVII - 4.7b: X-ray powder diffraction diagram of Bes5 = besylate, form V
(anhydrous form) Figure XVIII - 4.8: X-ray powder diffraction diagram of Cas2 = camphorsulfonate, form II (anhydrous form)
Figure XIX - 4.9a: X-ray powder diffraction diagram of Nds3 = naphthalene- 1,5- disulfonate, form III Figure XX - 4.9b: X-ray powder diffraction diagram of Nds5 = naphthalene- 1,5- disulfonate, form V
Figure XXI - 4.10: X-ray powder diffraction diagram of Citl = citrate, form I Figure XXII - 4.11a: X-ray powder diffraction diagram of D-Tarl = D-tartrate, form I Figure XXIII - 4.12a: X-ray powder diffraction diagram of L-Tarl = L-tartrate, form I Figure XXIV - 4.1 Ib: X-ray powder diffraction diagram of D-Tar2 = D-tartrate, form II Figure XXV - 4.12b: X-ray powder diffraction diagram of L-Tar2 = L-tartrate, form II Figure XXVI - 4.13a: X-ray powder diffraction diagram of Fuml = fumarate, form I Figure XXVII - 4.13b: X-ray powder diffraction diagram of Fum3 = fumarate, form III Figure XXVIII - 4.14: X-ray powder diffraction diagram of Mae 1 = maleate, form I Figure XXIX - 4.15: X-ray powder diffraction diagram of GIc 1 = glycolate, form I Figure XXX - 4.16: X-ray powder diffraction diagram of GIy 1 = glycinate, form I Figure XXXI - 4.17a: X-ray powder diffraction diagram of L-MaIl = L-malate, form I Figure XXXII - 4.18a: X-ray powder diffraction diagram of D-MaIl = L-malate, form I Figure XXXIII - 4.17b: X-ray powder diffraction diagram of L-Mal2 = L-malate, form II
Figure XXXIV - 4.18b: X-ray powder diffraction diagram of D-MaB = D-malate, form
III
Figure XXXV - 4.19a: X-ray powder diffraction diagram of Maol = malonate, form I
Figure XXXVI - 4.19b: X-ray powder diffraction diagram of Mao2 = malonate, form II Figure XXXVII - 4.19c: X-ray powder diffraction diagram of Mao3 = malonate, form III
Figure XXXVIII - 4.19d: X-ray powder diffraction diagram of Mao4 = malonate, form IV Figure XXXIX - 4.19e: X-ray powder diffraction diagram of Mao6 = malonate, form VI Figure XL - 4.20a: X-ray powder diffraction diagram of Sucl = succinate, form I Figure XLI - 4.20b: X-ray powder diffraction diagram of Suc2 = succinate, form II Figure XLII - 4.21a: X-ray powder diffraction diagram of Oxa3 = oxalate, form III Figure XLIII - 4.21b: X-ray powder diffraction diagram of Oxa5 = oxalate, form V Figure XLIV - 4.21c: X-ray powder diffraction diagram of Oxa6 = oxalate, form VI Figure XLV - 4.22: X-ray powder diffraction diagram of Genl = gentisate, form I Figure XLVI - 4.23a: X-ray powder diffraction diagram of Cam2 = camphorate, form II Figure XLVII - 4.23b: X-ray powder diffraction diagram of Cam3 = camphorate, form III
Figure XLVIII - 4.24a: X-ray powder diffraction diagram of Ben2 = benzoate, form II Figure XLIX - 4.24b: X-ray powder diffraction diagram of Ben3 = benzoate, form III Figure L - 4.25a X-ray powder diffraction diagram of Sac3 = saccharinate, form III Figure LI - 4.25b: X-ray powder diffraction diagram of Sac5 = saccharinate, form V Figure LII - 4.26: X-ray powder diffraction diagram of Sail = salicylate, form I Figure LIII - 4.27a: X-ray powder diffraction diagram of L- Asp 1 = L-aspartate, form I Figure LIV - 4.27b: X-ray powder diffraction diagram of L-Asp2 = L-aspartate, form II Figure LV - 4.28a: X-ray powder diffraction diagram of Ascl = ascorbate, form I Figure LVI - 4.28b: X-ray powder diffraction diagram of Asc3 = ascorbate, form III Figure LVII - 4.28c: X-ray powder diffraction diagram of Asc4 = ascorbate, form IV
The values of the X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) as recorded for the crystalline salt forms in accordance with the present invention are displayed in the following Tables. For each crystalline salt form, the highest values of d[A] in the corresponding Table characterizes this crystalline salt form.
Table I - 4.1a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of HCH = chloride, form I (anhydrous)
Figure imgf000046_0001
Figure imgf000047_0001
Table Il - 4.1b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of HCI2 = chloride, form Il (hydrated form)
Figure imgf000047_0002
Figure imgf000048_0001
Table III - 4.2a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of HBr7 = bromide, form VII (anhydrous form)
Figure imgf000049_0001
Figure imgf000050_0001
Table IV - 4.2b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of HBrδ = bromide, form VIII
Figure imgf000050_0002
Figure imgf000051_0001
Table V - 4.3 X-ray powder reflections (up to 30 !Θ) and intensities (normalized) of Pho1 = phosphate, form I
Figure imgf000051_0002
Figure imgf000052_0001
Table Vl - 4.4a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of SuH = sulfate, form I (hydrated form)
Figure imgf000052_0002
Figure imgf000053_0001
Table VII - 4.4b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Sul5 = sulfate, form V
Figure imgf000053_0002
Figure imgf000054_0001
Table VIII - 4.4c X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Sul6 = sulfate, form Vl (hydrated form)
Figure imgf000055_0001
Figure imgf000056_0001
Table IX - 4.4d X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Sul7 = sulfate, form VII
Figure imgf000056_0002
Figure imgf000057_0001
Table X - 4.5a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Eds1 = edisylate, form I
Figure imgf000057_0002
Figure imgf000058_0001
Figure imgf000059_0001
Table Xl - 4.5b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Eds2 = edisylate, form Il
Figure imgf000059_0002
Figure imgf000060_0001
Table XII - 4.5c X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Eds5 = edisylate, form V
Figure imgf000060_0002
Figure imgf000061_0001
Table XIII - 4.5d X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Eds6 = edisylate, form Vl
Figure imgf000061_0002
Figure imgf000062_0001
Table XIV - 4.6a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Ise2 = isethionate, form Il
Figure imgf000062_0002
Figure imgf000063_0001
Table XV - 4.6b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Ise4 = isethionate, form IV
Figure imgf000063_0002
Figure imgf000064_0001
Table XVI - 4.7a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Bes3 = besylate, form III
Figure imgf000064_0002
Table XVII - 4.7b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Bes5 = besylate, form V
Figure imgf000065_0001
Figure imgf000066_0001
Table XVIII - 4.8 X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Cas2 = camphorsulfonate, form Il
Figure imgf000066_0002
Figure imgf000067_0001
Table XIX - 4.9a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Nds3 = naphthalene-1,5-disulfonate, form
Figure imgf000067_0002
Figure imgf000068_0001
Table XX - 4.9b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Nds5 = naphthalene-1,5-disulfonate, form V
Figure imgf000068_0002
Figure imgf000069_0001
Table XXI - 4.10 X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Cit1 = citrate, form I
Figure imgf000069_0002
Figure imgf000070_0001
Table XXII - 4.11a X-ray powder reflections (up to 30 c Θ) and intensities (normalized) of D-TaM = D-tartrate, form I
Figure imgf000070_0002
Figure imgf000071_0001
Table XXIII - 4.12a X-ray powder reflections (up to 30 and intensities (normalized) of L-TaM = L-tartrate, form I
Figure imgf000071_0002
Figure imgf000072_0001
Table XXIV - 4.11b X-ray powder reflections (up to 30 Θ) and intensities (normalized) of D-Tar2 = D-tartrate, form Il
Figure imgf000073_0001
Table XXV - 4.12b X-ray powder reflections (up to 30 and intensities (normalized) of L-Ta r2 = L-tartrate, form Il
Figure imgf000074_0001
Figure imgf000075_0001
Table XXVI - 4.13a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Fum1 = fumarate, form I
Figure imgf000075_0002
Figure imgf000076_0001
Table XXVII - 4.13b X-ray powder reflections (up to 30 and intensities (normalized) of Fum3 = fumarate, form III
Figure imgf000076_0002
Figure imgf000077_0001
Table XXVIII - 4.14 X-ray powder reflections (up to 30 and intensities (normalized) of Mae1 = maleate, form I
Figure imgf000077_0002
Figure imgf000078_0001
Table XXIX - 4.15 X-ray powder reflections (up to 30 Θ) and intensities (normalized) of GId = glycolate, form I
Figure imgf000078_0002
Figure imgf000079_0001
Table XXX - 4.16 X-ray powder reflections (up to 30 Θ) and intensities (normalized) of GIyI = glycinate, form I
Figure imgf000079_0002
Figure imgf000080_0001
Table XXXI - 4.17a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of L-MaH = L-malate, form I
Figure imgf000080_0002
Figure imgf000081_0001
Table XXXII - 4.1δa X-ray powder reflections (up to 30 Θ) and intensities (normalized) of D-MaH = D-malate, form I
Figure imgf000082_0001
Figure imgf000083_0001
Table XXXIII - 4.17b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of L-Ma I2 = L-malate, form Il
Figure imgf000083_0002
Figure imgf000084_0001
Table XXXIV - 4.18b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of D-Mal3 = D-malate, form III
Figure imgf000084_0002
Figure imgf000085_0001
Table XXXV - 4.19a X-ray powder reflections (up to 30 and intensities (normalized) of Mao1 = malonate, form I
Figure imgf000085_0002
Figure imgf000086_0001
Table XXXVI - 4.19b X-ray powder reflections (up to 30 Θ) and intensities (normalized) of Mao2 = malonate, form Il
Figure imgf000086_0002
Figure imgf000087_0001
Table XXXVII - 4.19c X-ray powder reflections (up to 30 Θ) and intensities (normalized) of Mao3 = malonate, form III
Figure imgf000088_0001
Figure imgf000089_0001
Table XXXVIII - 4.19d X-ray powder reflections (up to 30 !Θ) and intensities (normalized) of Mao4 = malonate, form IV
Figure imgf000089_0002
Figure imgf000090_0001
Table XXXIX - 4.19e X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Mao6 = malonate, form Vl
Figure imgf000090_0002
Figure imgf000091_0001
Table XL - 4.20a X-ray powder reflections (up to 30 ' Θ) and intensities (normalized) of Sud = succinate, form I
Figure imgf000091_0002
Figure imgf000092_0001
Table XLI - 4.20b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Suc2 = succinate, form Il
Figure imgf000092_0002
Figure imgf000093_0001
Table XLII - 4.21a X-ray powder reflections (up to 30 Θ) and intensities (normalized) of Oxa3 = oxalate, form III
Figure imgf000094_0001
Table XLIII - 4.21b X-ray powder reflections (up to 30 !Θ) and intensities (normalized) of Oxa5 = oxalate, form V
Figure imgf000095_0001
Table XLIV - 4.21c X-ray powder reflections (up to 30 !Θ) and intensities (normalized) of Oxa6 = oxalate, form Vl
Figure imgf000096_0001
Table XLV - 4.22 X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Gen1 = gentisate, form I
Figure imgf000097_0001
Figure imgf000098_0001
Table XLVI - 4.23a X-ray powder reflections (up to 30 ° \ and intensities (normalized) of Cam2 = camphorate, form Il
Figure imgf000098_0002
Figure imgf000099_0001
Table XLVII - 4.23b X-ray powder reflections (up to 30 and intensities (normalized) of Cam2 = camphorate, form I
Figure imgf000099_0002
Figure imgf000100_0001
Table XLVIII - 4.24a X-ray powder reflections (up to 30 !Θ) and intensities (normalized) of Ben2 = benzoate, form Il
Figure imgf000100_0002
Figure imgf000101_0001
Table XLIX - 4.24b X-ray powder reflections (up to 30 Θ) and intensities (normalized) of Ben3 = benzoate, form III
Figure imgf000102_0001
Figure imgf000103_0001
Table L - 4.25a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Sac3 = saccharinate, form III
Figure imgf000103_0002
Figure imgf000104_0001
Table LI - 4.25b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Sac5 = saccharinate, form V
Figure imgf000104_0002
Figure imgf000105_0001
Table LII - 4.26 X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Sail = salicylate, form I
Figure imgf000105_0002
Figure imgf000106_0001
Table LIII - 4.27a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of L-Asp1 = L-aspartate, form I
Figure imgf000106_0002
Figure imgf000107_0001
Table LIV - 4.27b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of L-As p2 = L-aspartate, form Il
Figure imgf000107_0002
Figure imgf000108_0001
Table LV - 4.28a X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Asc1 = ascorbate, form I
Figure imgf000109_0001
Table LVI - 4.28b X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Asc3 = ascorbate, form III
Figure imgf000110_0001
Figure imgf000111_0001
Table LVII - 4.28c X-ray powder reflections (up to 30 ° 2Θ) and intensities (normalized) of Asc4 = ascorbate, form IV
Figure imgf000111_0002
Figure imgf000112_0001
Thus, in accordance with one preferred embodiment, the present invention relates to the following salts and/or crystalline forms and/or crystalline salt forms of the compound 3- Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone:
Crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, in particular in hemihydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α, β, γ and of the cell volume V as given in above Table 3.1;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride, in particular in crystalline anhydrous Form I as characterized in above Table 2; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride, in particular in crystalline hydrated Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide, in particular in crystalline hydrated Form II, more particularly in the form of its trihydrate, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α, β, γ and of the cell volume V as given in above Table 3.2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide, in particular in crystalline anhydrous Form VII as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide, in particular in crystalline anhydrous Form VIII as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate, in particular in crystalline Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate, in particular in crystalline hydrated Form II, more particularly in its 3,5 - hydrate form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.3;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline hydrated Form I as characterized in above Table 2; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline Form V as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline hydrated Form VI as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline hydrated Form VII as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone methanesulfonate, in particular in crystalline hydrated Form I, more particularly in its hemihydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.4;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate, in particular in its crystalline Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate, in particular in its crystalline Form II as characterized in above Table 2; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline hydrated Form III as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate, in particular in its crystalline hydrated Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form V as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate, in particular in its crystalline Form V as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form VI as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate, in particular in its crystalline Form VI as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in crystalline anhydrous Form I, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.5; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in its crystalline Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in its crystalline Form IV as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in crystalline hydrated Form V, more particularly in its dihydrate form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.5;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate, in particular in crystalline hydrated Form I, more particularly in its trihydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.7;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate, in particular in its crystalline Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate, in particular in its crystalline Form V as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate, in particular in crystalline hydrated Form I, more particularly in its monohydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.8; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate, in particular in crystalline hydrated Form II, more particularly in its trihydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.9;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in its crystalline anhydrous Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in crystalline anhydrous Form III, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.10;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in crystalline solvated Form V, more particularly in its hemisolvated form with propionitrile, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, cc, β, γ and of the cell volume V as given in above Table 3.11;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in crystalline solvated Form XII, more particularly in its hemisolvated form with 1,2- dimethoxyethane, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, cc, β, γ and of the cell volume V as given in above Table 3.12; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1 ,5-disulfonate, in particular in its crystalline Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1 ,5-disulfonate, in particular in its crystalline hydrated Form V as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate, in particular in its crystalline anhydrous Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate, in particular in its crystalline anhydrous Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne} citrate, in particular in its crystalline hydrated Form II, more particularly in its dihydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.13;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-tartrate, in particular in its crystalline Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate, in particular in its crystalline hydrated Form I as characterized in above Table 2; Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-tartrate, in particular in its crystalline Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} fumarate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} fumarate, in particular in its crystalline anhydrous Form III as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}maleate, in particular in its crystalline anhydrous Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate, in particular in crystalline hydrated Form I, more particularly in its 2.5-hydrated form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.14;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycinate, in particular in its crystalline Form I as characterized in above Table 2; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate, in particular in its crystalline Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-malate, in particular in its crystalline Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-malate, in particular in its crystalline hydrated Form III, more particularly in its tetrahydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α, β, γ and of the cell volume V as given in above Table 3.15;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-malate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-malate, in particular in its crystalline Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline hydrated Form I as characterized in above Table 2; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate, in particular in its crystalline hydrated Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline hydrated Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline hydrated and/or solvated Form III as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline Form IV as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline Form VI as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate, in particular in its crystalline hydrated Form II as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate, in particular in its crystalline hydrated Form III, more particularly in its hexahydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α, β, γ and of the cell volume V as given in above Table 3.16;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate, in particular in its crystalline hydrated Form III as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne} oxalate, in particular in its crystalline hydrated Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate, in particular in its crystalline Form V as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne} oxalate, in particular in its crystalline Form V as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne} oxalate, in particular in its crystalline hydrated Form VI as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate, in particular in crystalline hydrated Form XI, more particularly in its hemihydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α, β, γ and of the cell volume V as given in above Table 3.17; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate, in particular in its crystalline hydrated Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate, in particular in its crystalline Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate, in particular in its crystalline hydrated Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate, in particular in its crystalline Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate, in particular in crystalline hydrated Form I, more particularly in its monohydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α, β, γ and of the cell volume V as given in above Table 3.18;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate, in particular in its crystalline Form III as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate, in particular in its crystalline hydrated Form V as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate, in particular in its crystalline Form I as characterized in above Table 2; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate, in particular in crystalline anhydrous Form II, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, CC, β, γ and of the cell volume V as given in above Table 3.19;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-aspartate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-aspartate, in particular in its crystalline Form II as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone xinafoate, in particular in crystalline hydrated Form I, more particularly in its monohydrate form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.20;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate, in particular in its crystalline Form I as characterized in above Table 2;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate, in particular in its crystalline Form III as characterized in above Table 2; and
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate, in particular in its crystalline Form IV as characterized in above Table 2. A further object of the present invention is the use of the above salts and crystalline salt forms as medicament.
A further object of the present invention is the use of the above salts and crystalline salt forms as medicament for the treatment or prevention of the following diseases.
The diseases which can be treated by the salts and crystal salt forms of the compound of formula (I) in accordance with the present invention are all kind of diseases in which cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis are involved, which can be of oncological nature such as all types of malignant neoplasias or cancers, or of non-oncological nature, such as diabetic retinopathy, rheumatoid arthritis, or psoriasis.
Among cancers, selected specific target indications are solid tumours, such as urogenital cancers (such as prostate cancer, renal cell cancers, bladder cancers), gynecological cancers (such as ovarian cancers, cervical cancers, endometrial cancers), lung cancer, gastrointestinal cancers (such as colorectal cancers, pancreatic cancer, gastric cancer, oesophageal cancers, hepatocellular cancers, cholangiocellular cancers), head and neck cancer, malignant mesothelioma, breast cancer, malignant melanoma or bone and soft tissue sarcomas, and haematologic neoplasias, such as multiple myeloma, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome and acute lymphoblastic leukemia. Of special interest is the treatment of hormone sensitive or hormone refractory prostate cancer, ovarian carcinoma, non small cell lung cancer, small cell lung cancer, or multiple myeloma. Preferably, the underlying mechanism by which the above-mentioned diseases may be treated is via antagonism of at least one receptor selected from VEGFR 1 to 3, PDGFRα and β, FGFRl, 2 and 3, EGFR, HER2, IGFlR, HGFR, c-Kit, or a src tyrosine kinase family member.
In a further embodiment, the diseases which can be treated by the salts and crystal salt forms of the compound of formula (I) in accordance with the present invention are also diseases which result from aberrant activity of the following tyrosine kinases: ABL, FGFR3, FLT3 and RET. Such diseases are, for example, Kidney Wilm's tumor, soft tissue osteosarcoma, glioblastoma multiforme, Ph+ leukemias such as chronic myelogeneous leukemia (CML) or acute lymphocytic leukemia (ALL), epithelial cancers such as bladder and cervix cancers, multiple myeloma, hepatocellular carcinoma, skeletal abnormalities such as achondroplasia and hypochondraplasia, leukemias including acute myeloid leukemia (AML), AML with trilineage myelodysplasia (AML/TMDS), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), cancers of the nerve tissue such as neuroblastoma, multiple endocrine neoplasias type 2A and 2B (MEN2A and MEN2B), familial medullary thyroid carcinomas (FMTC), papillary thyroid carcinomas (PTC) and breast cancer.
In yet another embodiment, the diseases which may be treated with the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are immunologic disease or pathological condition involving an immunologic component. Such diseases are, for example, autoimmune diseases, for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from inflammatory bowel disease (e.g. colitis ulcerosa and Morbus Crohn), rheumatoid arthritis, glomerulonephritis and lung fibrosis, psoriasis, psoriasis arthritis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes, and indications which need immunosuppressant therapy, for instance prevention or therapy of tissue or organ transplant rejection. Preferably, the underlying mechanism by which the above-mentioned diseases may be treated is via antagonism of the Lck tyrosine kinase, a tyrosine kinase belonging to the src family.
It has further been surprisingly found that the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are suitable for the treatment of specific fibrotic diseases selected from the group consisting of fibrosis and remodeling of lung tissue in chronic obstructive pulmonary disease, fibrosis and remodeling of lung tissue in chronic bronchitis, fibrosis and remodeling of lung tissue in emphysema, lung fibrosis and pulmonary diseases with a fibrotic component, fibrosis and remodeling in asthma, fibrosis in rheumatoid arthritis, virally induced hepatic cirrhosis, radiation- induced fibrosis, post angioplasty restenosis, chronic glomerulonephritis, renal fibrosis in patients receiving cyclosporine and renal fibrosis due to high blood pressure, diseases of the skin with a fibrotic component, and excessive scarring. Amongst these diseases, preferred diseases which my be treated with the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are lung fibrosis and pulmonary diseases with a fibrotic component selected from idiopathic pulmonary fibrosis, giant cell interstitial pneumonia, sarcodosis, cystic fibrosis, respiratory distress syndrome, drug-induced lung fibrosis, granulomatosis, silicosis, asbestosis, systemic scleroderma, the virally induced hepatic cirrhosis selected from hepatitis C induced hepatic cirrhosis, and the diseases of the skin with a fibrotic component selected from scleroderma, sarcodosis and systemic lupus erythematosus.
Thus, the present invention further relates to the use of the salts and crystal salt forms of the compound of above formula (I) for the preparation of a medicament for the treatment or prevention of the above-mentioned fibrotic diseases.
Within the meaning of the present invention, the treatment of the diseases may also be via simultaneous, separate or sequential co-administration of effective amounts of one or more salts and crystal salt forms of the compound of formula (I) in accordance with the present invention and at least a further chemotherapeutic or naturally occurring, semi- synthetic or synthetic therapeutic agent, in the form of a combined preparation, which if necessary may optionally be adapted for a co-treatment with radiotherapy or radio-immunotherapy.
The present invention also relates to a process for the treatment of the above-mentioned diseases, characterized in that one or more of the above-mentioned salts or crystal salt forms of the compound of formula (I) are administered in therapeutically effective amounts to a patient in need thereof.
The present invention further relates to processes for the treatment of the aforementioned diseases, characterized in that one or more of the above-mentioned salts or crystal salt forms of the compound of formula (I) are administered once or several times a day or once or several times a week in therapeutically effective amounts.
The present invention also relates to pharmaceutical compositions comprising the above-mentioned salts or crystalline salt forms. In the treatment of the aforementioned diseases, the physicochemical properties of a drug substance may influence decisively stability, usefulness and efficacy of the formulation. In this respect the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention show advantageous properties not yet disclosed in the art.
Suitable preparations for the pharmaceutical compositions in accordance with the present invention include for example tablets, capsules, suppositories, solutions, - particularly solutions for injection (s.c, Lv., i.m.) and infusion - elixirs, emulsions or dispersible powders. The proportion of the pharmaceutically active compound(s) should be in the range from 0.01 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage necessary to achieve a therapeutic effect. If necessary the doses specified may be given several times a day.
Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
The preparations are administered by the usual methods, preferably by oral route, by injection or transdermally. For oral administration the tablets may of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
For parenteral use, solutions of the active substances with suitable liquid carriers may be used.
The dosage for intravenous use is from 1 - 1000 mg per hour, preferably between 5 and 500 mg per hour.
However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.
The following examples of pharmaceutical formulations illustrate the present invention without representing a limitation of its scope.
1. Coated tablet containing 75 mg of active substance
Composition : 1 tablet core contains active substance calcium phosphate polyvinylpyrrolidone carboxymethylcellulose sodium silicon dioxide magnesium stearate
Figure imgf000130_0001
Preparation (direct compression): The active substance is mixed with all components, sieved and compressed in a tablet-making machine to form tablets of the desired shape.
Weight of core: 230 mg Appearance of core: 9 mm, biconvex
The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose.
Weight of coated tablet: 240 mg.
2. Tablet containing 100 mg of active substance
Composition : 1 tablet contains active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg hydroxypropylmethylcellulose 4.0 mg magnesium stearate 2.0 mg 220.0 mg
Preparation (wet granulation):
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the hydroxypropylmethylcellulose. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 500C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg Appearance of tablet: 10 mm, flat faced with bevelled edges and breaking notch on one side
3. Tablet containing 150 mg of active substance Composition: 1 tablet contains active substance 150.0 mg lactose 85.0 mg microcrystalline cellulose 40.0 mg polyvinylpyrro lidone 10.0 mg silicon dioxide 10.0 mg magnesium stearate 5.0 mg
300.0 mg
Preparation (dry granulation):
The active substance mixed with lactose, polyvinylpyrrolidone,and parts of the microcrystalline cellulose, magnesium stearate is compacted e.g. on a roller compactor. The ribbons are broken up in fine granules through a screen with a mesh size of 0.8 mm. After subsequent sieving through a screen with a mesh size of 0.5 mm and blending with the remaining components, tablets are pressed from the mixture.
Weight of tablet: 300 mg Appearance of tablet: 10 mm, flat
4. Hard gelatine capsule containing 150 mg of active substance
Composition: 1 capsule contains active substance 150.0 mg lactose 85.0 mg microcrystalline cellulose 40.0 mg polyvinylpyrrolidone 10.0 mg silicon dioxide 10.0 mg magnesium stearate 5.0 mg
300.0 mg
Preparation: The active substance mixed with lactose, polyvinylpyrrolidone,and parts of the microcrystalline cellulose, magnesium stearate is compacted e.g. on a roller compactor. The ribbons are broken up in fine granules through a screen with a mesh size of 0.8 mm. After subsequent sieving through a screen with a mesh size of 0.5 mm and blending with the remaining components, the finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 300 mg Capsule shell: size 1 hard gelatine capsule
5. Suppository containing 150 mg of active substance
1 suppository contains: active substance 150.0 mg polyethyleneglycol 1500 800.0 mg polyethyleneglycol 6000 850.0 mg polyoxyl 40 hydrogenated castor oil 200.0 mg
2,000.0 mg
Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
6. Suspension containing 50 mg of active substance
100 ml of suspension contains: active substance 1.00 g carboxymethylcellulose sodium 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.0O g
70% sorbitol solution 20.00 g flavouring 0.3O g dist. water ad 100 ml
Preparation:
The distilled water is heated to 700C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
Thus, 5 ml of suspension contains 50 mg of active substance.
7. Ampoule containing 10 mg active substance
Composition:
active substance 10.0 mg
0.01 N hydrochloric acid q.s. double-distilled water ad 2.0 ml
Preparation: The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with sodium chloride, filtered sterile and transferred into a 2 ml ampoule.
8. Ampoule containing 50 mg of active substance
Composition: active substance 50.0 mg
0.01 N hydrochloric acid q.s. double-distilled water ad 10.0 ml
Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with sodium chloride, filtered sterile and transferred into a 10 ml ampoule.
9. Capsule for powder inhalation containing 5 mg of active substance
1 capsule contains: active substance 5.0 mg lactose for inhalation 15.0 mg
20.0 mg Preparation: The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg).
Weight of capsule: 70.0 mg Size of capsule = size 3
10. Solution for inhalation for a hand-held nebuliser containing 2.5 mg active substance
1 spray contains: active substance 2.500 mg benzalkonium chloride 0.001 mg
IN hydrochloric acid q.s. ethano I/water (50/50) ad 15.000 m
Preparation:
The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50). The pH of the solution is adjusted with IN hydrochloric acid. The resulting solution is filtered and transferred into suitable containers for use in hand- held nebulisers (cartridges).
Contents of the container: 4.5 g

Claims

Patent Claims
1. Salt of the compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)- N-methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone, which is selected from the group consisting of:
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone methanesulfonate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate; the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1,5- disulfonate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-tartrate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-tartrate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} fumarate; the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}maleate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycinate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-malate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-malate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-malate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate; the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} oxalate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate;
the bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-aspartate;
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone xinafoate; and
the 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate.
2. Crystalline salt form of the compound 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)- methylcarbonyl)-N-methyl-amino)-anilino)-l -phenyl-methylene] -6-methoxycarbonyl-2- indolinone, which is selected from the group consisting of:
crystalline anhydrous 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide;
crystalline anhydrous 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate; crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone methanesulfonate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2- indo lino ne } ethanedisulfo nate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate;
crystalline hydrated bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2- indo lino ne } ethanedisulfo nate;
crystalline anhydrous 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate; crystalline hydrated 3 -Z- [ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate;
crystalline anhydrous 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate;
crystalline solvated 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1,5- disulfonate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1,5-disulfonate;
crystalline anhydrous 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate;
crystalline hydrated bis{3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate; crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone D- tartrate;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}D-tartrate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L- tartrate;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-tartrate;
crystalline hydrated bis{3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2- indolinone} fumarate;
crystalline anhydrous bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2- indolinone} fumarate;
crystalline anhydrous bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2- indolinone}maleate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L- lactate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate; crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycinate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L- malate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-malate;
crystalline hydrated bis{3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L- malate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone D- malate;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}D-malate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate;
crystalline hydrated bis{3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2- indo lino ne } malo nate ; crystalline solvated bis {3-Z-[ l-(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2- indo lino ne } malo nate ;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne}malo nate;
crystalline hydrated bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2- indo lino ne} succinate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate;
crystalline hydrated bis{3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} oxalate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate;
crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} oxalate;
crystalline hydrated bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} oxalate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate; crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate;
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate;
crystalline anhydrous 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N- methyl-amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate;
crystalline hydrated bis{3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L- aspartate; crystalline bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl- amino)-anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-aspartate;
crystalline hydrated 3-Z-[l-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N- methyl-amino)-anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone xinafoate; and
crystalline 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate.
3. Crystalline salt form of the compound 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)- methylcarbonyl)-N-methyl-amino)-anilino)-l -phenyl-methylene] -6-methoxycarbonyl-2- indolinone in accordance with claim 2, which is selected from the group consisting of:
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride in crystalline anhydrous Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride in crystalline hydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide in crystalline trihydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide in crystalline anhydrous Form VII; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide in crystalline anhydrous Form VIII;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate in crystalline Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate in crystalline 3,5 - hydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate in crystalline hydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate in crystalline Form V;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate in crystalline hydrated Form VI;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate in crystalline hydrated Form VII;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone methanesulfonate in crystalline hemihydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate in crystalline Form I; bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate in crystalline Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 ■ phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate in crystalline Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate in crystalline Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 ■ phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate in crystalline hydrated Form III;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate in crystalline hydrated Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 ■ phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate in crystalline Form V;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate in crystalline Form V;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 ■ phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate in crystalline Form VI; Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} ethanedisulfonate in crystalline Form VI;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate in crystalline anhydrous Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate in crystalline Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate in crystalline Form IV;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate in crystalline dihydrated Form V;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate in crystalline trihydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate in crystalline Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate in crystalline Form V;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate in crystalline monohydrated Form I; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate in crystalline trihydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate in crystalline anhydrate Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate in crystalline anhydrous Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate in crystalline hemisolvated Form V with propionitrile;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate in hemisolvated Form XII with 1 ,2-dimethoxyethane;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1 ,5-disulfonate in crystalline Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene- 1 ,5-disulfonate in crystalline hydrated Form V;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate in crystalline anhydrous Form I; Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)-l-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate in crystalline anhydrous Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate in crystalline dihydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate in crystalline hydrated Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-tartrate in crystalline Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate in crystalline hydrated Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-tartrate in crystalline Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} fumarate in crystalline hydrated Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne} fumarate in crystalline anhydrous Form III; Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}maleate in crystalline anhydrous Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate in crystalline 2,5- hydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate in crystalline hydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycinate in crystalline Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate in crystalline hydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate in crystalline Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-malate in crystalline Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-malate in crystalline tetrahydrated Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-malate in crystalline hydrated Form I; Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-malate in crystalline Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate in crystalline hydrated Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate in crystalline hydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate in crystalline hydrated Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate in crystalline hydrated Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate in crystalline hydrated and/or solvated Form III;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate in crystalline Form IV;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate in crystalline Form VI; Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate in crystalline hydrated Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate in crystalline hydrated Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} succinate in crystalline hexahydrated Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate in crystalline hydrated Form III;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} oxalate in crystalline hydrated Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate in crystalline Form V;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne} oxalate in crystalline Form V;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} oxalate in crystalline hydrated Form VI; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate in crystalline hydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate in crystalline hemihydrated Form XI;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate in crystalline hydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate in crystalline Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate in crystalline hydrated Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate; in crystalline Form III;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate in crystalline monohydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate in crystalline Form III; 3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate in crystalline hydrated Form V;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate in crystalline Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate in crystalline anhydrous Form II;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-aspartate in crystalline hydrated Form I;
Bis {3-Z-[ 1 -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)- anilino)- 1 -phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-aspartate in crystalline Form II;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone xinafoate in crystalline monohydrated Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate in crystalline Form I;
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate in crystalline Form III; and
3-Z-[I -(4-(N-((4-methyl-piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 - phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate in crystalline Form IV.
4. Salt or crystalline salt form in accordance with any one of claims 1 to 3 for its use as medicament.
5. Pharmaceutical composition comprising a salt or a crystalline salt form in accordance with any one of claims 1 to 3, together with one or more inert carriers or diluents.
PCT/EP2007/055541 2006-06-08 2007-06-06 Salts and crystalline salt forms of an 2-indolinone derivative WO2007141283A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002653527A CA2653527A1 (en) 2006-06-08 2007-06-06 New salts and crystalline salt forms of an indolinone derivative
AU2007255393A AU2007255393A1 (en) 2006-06-08 2007-06-06 Salts and crystalline salt forms of an 2-indolinone derivative
BRPI0711956-9A BRPI0711956A2 (en) 2006-06-08 2007-06-06 crystalline salts and salt forms of an indolinone derivative
EP07729916A EP2029533A2 (en) 2006-06-08 2007-06-06 Salts and crystalline salt forms of an 2-indolinone derivative
MX2008015646A MX2008015646A (en) 2006-06-08 2007-06-06 Salts and crystalline salt forms of an 2-indolinone derivative.
JP2009513684A JP2009539798A (en) 2006-06-08 2007-06-06 2-indolinone derivative salt and crystalline salt form
US12/303,278 US20090318471A1 (en) 2006-06-08 2007-06-06 New Salts and Crystalline Salt Forms of an Indolinone Derivative
IL195679A IL195679A0 (en) 2006-06-08 2008-12-03 Salts and crystalline salt forms of an 2-indolinone derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06115159.3 2006-06-08
EP06115159A EP1870400A1 (en) 2006-06-08 2006-06-08 Salts and crystalline salt forms of an 2-indolinone derivative

Publications (2)

Publication Number Publication Date
WO2007141283A2 true WO2007141283A2 (en) 2007-12-13
WO2007141283A3 WO2007141283A3 (en) 2008-03-06

Family

ID=37231603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/055541 WO2007141283A2 (en) 2006-06-08 2007-06-06 Salts and crystalline salt forms of an 2-indolinone derivative

Country Status (13)

Country Link
US (1) US20090318471A1 (en)
EP (7) EP1870400A1 (en)
JP (1) JP2009539798A (en)
KR (1) KR20090026334A (en)
CN (1) CN101466675A (en)
AU (1) AU2007255393A1 (en)
BR (1) BRPI0711956A2 (en)
CA (1) CA2653527A1 (en)
IL (1) IL195679A0 (en)
MX (1) MX2008015646A (en)
RU (1) RU2008151506A (en)
WO (1) WO2007141283A2 (en)
ZA (1) ZA200808746B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081817A1 (en) 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
WO2011134898A1 (en) 2010-04-27 2011-11-03 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
JP2011529470A (en) * 2008-07-29 2011-12-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New compounds
CN102334030A (en) * 2009-03-12 2012-01-25 贝林格尔.英格海姆国际有限公司 Method or system using biomarkers for the monitoring of a treatment
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
WO2014180955A1 (en) 2013-05-10 2014-11-13 Boehringer Ingelheim International Gmbh Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
EP2985025A1 (en) 2008-06-06 2016-02-17 Boehringer Ingelheim International Gmbh Pharmaceutical combination
WO2017142002A1 (en) * 2016-02-17 2017-08-24 大正製薬株式会社 Crystal forms of free c-4"-substituted macrolide compound and salt thereof, and production methods therefor
WO2017144029A1 (en) 2016-02-24 2017-08-31 Zentiva, K.S. Crystalline modifications of methyl (3z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino} phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1h-indole-6-carboxylate salts and methods of preparation thereof
WO2017178428A1 (en) 2016-04-13 2017-10-19 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017203027A1 (en) 2016-05-27 2017-11-30 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019081235A1 (en) 2017-10-23 2019-05-02 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2021198253A1 (en) 2020-04-01 2021-10-07 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
US11261158B2 (en) 2017-11-17 2022-03-01 Fermion Oy Synthesis of 2-indolinone derivatives
US11560376B2 (en) 2018-03-07 2023-01-24 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104003925B (en) * 2013-06-05 2016-03-30 四川大学 Oxindole compounds or derivatives thereof and uses thereof
CN106008308A (en) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 Nintedanib ethanesulfonate crystal
PT3507276T (en) 2016-09-02 2022-01-11 Gilead Sciences Inc Toll like receptor modulator compounds
TWI632133B (en) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 Crystalline forms of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
CN109758437A (en) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 A kind of Neulized inhalation Nintedanib freeze-dried lipidosome preparation and preparation method thereof
TW202210480A (en) * 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027081A1 (en) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg 6-position substituted indoline, production and use thereof as a medicament
WO2004096224A2 (en) * 2003-04-29 2004-11-11 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027081A1 (en) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg 6-position substituted indoline, production and use thereof as a medicament
WO2004096224A2 (en) * 2003-04-29 2004-11-11 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2985025A1 (en) 2008-06-06 2016-02-17 Boehringer Ingelheim International Gmbh Pharmaceutical combination
JP2011529470A (en) * 2008-07-29 2011-12-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New compounds
US8853420B2 (en) 2008-07-29 2014-10-07 Boehringer Ingelheim International Gmbh Compounds
US20120157472A1 (en) * 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
WO2010081817A1 (en) 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
CN102334030A (en) * 2009-03-12 2012-01-25 贝林格尔.英格海姆国际有限公司 Method or system using biomarkers for the monitoring of a treatment
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
WO2011134898A1 (en) 2010-04-27 2011-11-03 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A3 (en) * 2010-11-19 2012-08-16 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2014180955A1 (en) 2013-05-10 2014-11-13 Boehringer Ingelheim International Gmbh Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
WO2017142002A1 (en) * 2016-02-17 2017-08-24 大正製薬株式会社 Crystal forms of free c-4"-substituted macrolide compound and salt thereof, and production methods therefor
US10532981B2 (en) 2016-02-24 2020-01-14 Zentiva K.S. Crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate salts and methods of preparation thereof
WO2017144029A1 (en) 2016-02-24 2017-08-31 Zentiva, K.S. Crystalline modifications of methyl (3z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino} phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1h-indole-6-carboxylate salts and methods of preparation thereof
WO2017178428A1 (en) 2016-04-13 2017-10-19 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017203027A1 (en) 2016-05-27 2017-11-30 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019081235A1 (en) 2017-10-23 2019-05-02 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
US11406638B2 (en) 2017-10-23 2022-08-09 Boehringer Ingelheim Internatinal Gmbh Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
US11813266B2 (en) 2017-10-23 2023-11-14 Boehringer Ingelheim International Gmbh Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
US11261158B2 (en) 2017-11-17 2022-03-01 Fermion Oy Synthesis of 2-indolinone derivatives
US11560376B2 (en) 2018-03-07 2023-01-24 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2021198253A1 (en) 2020-04-01 2021-10-07 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Also Published As

Publication number Publication date
BRPI0711956A2 (en) 2012-01-17
CA2653527A1 (en) 2007-12-13
EP1870400A1 (en) 2007-12-26
EP2364969A1 (en) 2011-09-14
IL195679A0 (en) 2009-09-01
ZA200808746B (en) 2009-05-27
CN101466675A (en) 2009-06-24
JP2009539798A (en) 2009-11-19
US20090318471A1 (en) 2009-12-24
EP2366689A1 (en) 2011-09-21
KR20090026334A (en) 2009-03-12
MX2008015646A (en) 2009-01-12
EP2364968A1 (en) 2011-09-14
EP2366690A1 (en) 2011-09-21
RU2008151506A (en) 2010-07-20
EP2366688A1 (en) 2011-09-21
AU2007255393A1 (en) 2007-12-13
EP2029533A2 (en) 2009-03-04
WO2007141283A3 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
EP2029533A2 (en) Salts and crystalline salt forms of an 2-indolinone derivative
JP7383652B2 (en) B-RAF Kinase Maleate Salt, Crystal Form, Preparation Method, and Use thereof
RU2526038C2 (en) Tosylate salt of 5-pyrazolyl-2-pyridone derivative effective in copd treatment
TWI675839B (en) Form crystal of bisulfate of janus kinase (jak) inhibitor and preparation method thereof
EP2093224A1 (en) Process for preparing eletriptan hydrobromide form beta
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
WO2020061996A1 (en) Novel crystal forms of deuterated azd9291 compound and use thereof
BRPI1009006B1 (en) 6- (1H-Imidazol-1-yl) -2-phenyl-quinazoline polymorphic form, its preparation process, formulation and pharmaceutical composition
WO2020164565A1 (en) New crystal form of oxypiperone hydrochloride and preparation method therefor
WO2015003571A1 (en) Novel crystal form of dabrafenib mesylate and preparation method thereof
KR20150002767A (en) CRYSTALLINE FORMS OF (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-ｄ]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE
WO2021213493A1 (en) Crystal form of dihydronaphthyridine compound and use thereof
US9365559B2 (en) Crystal form of Dabrafenib and preparation method of use thereof
US11059787B2 (en) Crystalline form of lenvatinib mesylate and methods thereof
CN102666528B (en) Crystalline CDC7 inhibitor salts
JP2022538042A (en) CDK kinase inhibitor
EP2238108B1 (en) Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
EP3960742A1 (en) Crystals of alkynyl-containing compound, salt and solvate thereof, preparation method, and applications
WO2023061437A1 (en) Salt of antitumor drug and crystal form thereof
EP3484872B1 (en) Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780021156.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07729916

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007729916

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2653527

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 195679

Country of ref document: IL

Ref document number: 12303278

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10116/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009513684

Country of ref document: JP

Ref document number: 12008502701

Country of ref document: PH

Ref document number: MX/A/2008/015646

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 574031

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007255393

Country of ref document: AU

Ref document number: 1020097000328

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008151506

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007255393

Country of ref document: AU

Date of ref document: 20070606

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0711956

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081208